Sufugolix
| CAS No. | 308831-61-0 | Cat. No. | BCP35686 |
| Name | Sufugolix | ||
| Synonyms | TAK-013; TAK013; TAK 013; | ||
| Formula | C36H31F2N5O4S | M. Wt | 667.73 |
| Description | Sufugolix is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.1 and 0.06 nM for affinity and in vitro inhibition, respectively). It was under development for the treatment of endometriosis and uterine leiomyoma and reached phase II clinical trials for both of these indications, but was subsequently discontinued. It seems to have been supplanted by relugolix (TAK-385), which is also under development by Takeda for the treatment of these conditions and has a more favorable drug profile (including reduced cytochrome P450 inhibition and improved in vivo GnRHR antagonistic activity) in comparison. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Glucagon Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.